Kyowa Hakko Kirin Co., Limited

Kyushu University

Kyoto University

Kirin Holdings Kabushiki Kaisha

Shinichiro Takayanagi

Yoshimasa Inagaki

Koichi Akashi

Yoshikane Kikushige

Tomonori Tawara

Shin Kaneko

Yohei Kawai

Ken Fukumoto

Sayaka Chuganji

Kazuki Nakazono

Atsushi Kunisato

The present invention relates to a method for producing T cells or NK cells including culturing T cells or NK cells in a culture medium containing a CaMKII inhibitor such as a bisbenzylisoquinoline alkaloid compound. The disclosed compounds and methods can be used for maintaining the undifferentiated state of undifferentiated T cells, or for efficiently proliferating T cells or NK cells.

Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells

Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(&#x2212;)CD34(+)CD38(&#x2212;) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).

Method for treatment of blood tumor using anti-TIM-3 antibody

The present invention provides an antibody to human IL-3R&#x3b1; chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R&#x3b1; chain but does not bind to C domain of the human IL-3R&#x3b1; chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R&#x3b1; is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R&#x3b1; as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R&#x3b1; is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R&#x3b1; antibody as an active ingredient.

Polynucleotide encoding antibody to human IL-3 receptor alpha chain

Antibody to human IL-3 receptor alpha chain

Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(&#x2212;)CD34(+)CD38(&#x2212;) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Also disclosed is a composition for preventing or treating blood tumor, which comprises a TIM-3 antibody as an active ingredient. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)), all of which are capable of expressing TIM-3. The diseases for which the therapeutic use is to be examined include blood diseases in which the expression of TIM-3 is observed in bone marrow or peripheral blood, particularly blood tumor.

Growing community of inventors

Tokyo, Japan

Shinichiro Takayanagi